Monthly Oncology Tumor Boards: A Multidisciplinary Approach to Individualized Patient Care - Ovarian Cancer

October 7, 2016

Join Richard Penson, MD and Laura Sullivan, RN from Massachusetts General Hospital Cancer Center as they present their expertise on a range of cases pertaining to ovarian cancer.

The NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®) Ovarian Cancer recommend primary surgery for most stages of ovarian cancer followed by postoperative systemic therapy unless patients have major comorbidities or other contraindications. The therapeutic benefit of neoadjuvant chemotherapy followed by interval cytoreduction is controversial. It may be considered for patients with bulky stage III to IV disease who are not surgical candidates; however, the NCCN Guidelines® for Ovarian Cancer recommend that a gynecologic oncologist should make this assessment before neoadjuvant chemotherapy is administered. The NCCN Guidelines for Ovarian Cancer are updated at least once a year. Multidisciplinary teams need to be aware of current NCCN recommendations when selecting systemic therapy for their patients with ovarian cancer.

Target Audience

This educational program is designed to meet the educational needs of oncologists, pathologists, nurses, pharmacists, case managers, and other health care professionals who manage patients with cancer.

Learning Objectives

Following this activity, participants should be able to:

  • Review NCCN recommendations for primary postoperative systemic therapy when developing a treatment plan for women with different types of ovarian cancer.
  • Individualize recurrence therapy for women with different types of ovarian cancer.
  • Counsel patients about potential side effects from different therapeutic agents.
Additional information
Supporters: 

This educational activity is supported by educational grants from Astellas; AstraZeneca; Bayer Healthcare Pharmaceuticals Inc.; Celgene Corporation; Eisai; Genomic Health, Inc.; Janssen Biotech, Inc.; Lilly; Novartis Pharmaceuticals Corporation; Sanofi-Genzyme; and Takeda Oncology. This activity is supported by educational funding provided by Amgen. This activity is supported by an independent medical education grant from Bristol-Myers Squibb. This educational activity is supported by an unrestricted education grant from Exelixis, Inc. This educational activity is supported by an independent educational grant from Merck.

Course summary
Available credit: 
  • 1.00 ACPE contact hours
  • 1.00 AMA PRA Category 1 Credit™
  • 1.00 ANCC contact hours
  • 1.00 CCM clock hours
  • 1.00 Participation
Course opens: 
10/06/2016
Course expires: 
11/30/2016
Event starts: 
10/07/2016 - 9:00am EDT
Event ends: 
10/07/2016 - 10:00am EDT
Cost:
$0.00
Add to calendar: 

Richard Penson, MD
Massachusetts General Hospital Cancer Center

Laura Sullivan, RN
Massachusetts General Hospital Cancer Center

 

Disclosure of Relevant Financial Relationships
All faculty and activity planners participating in NCCN continuing education activities are expected to disclose any relevant financial relationships with a commercial interest as defined by the ACCME’s, ANCC’s, and ACPE’s Standards for Commercial Support. All faculty presentations have been reviewed for adherence to the ACCME’s Criterion 7: The provider develops activities/educational interventions independent of commercial interests (SCS 1, 2, and 6) by experts on the topics. Full disclosure of faculty relationships will be made prior to the activity.

The faculty listed below has no relevant financial relationships to disclose:

Laura Sullivan, RN

The faculty listed below have disclosed the following relevant financial relationships:

Richard Penson, MD
AbbVie: Scientific Advisor
Amgen: Grant/Research Support
AstraZeneca: Grant/Research Support
Baxalta Oncology.: Scientific Advisor
Clovis Oncology: Scientific Advisor
Eisai Inc.: Grant/Research Support
Genentech Roche: Scientific Advisor
Vascular Biogenics Ltd: Grant/Research Support/Scientific Advisor

NCCN Staff Disclosures

The activity planning staff listed below has no relevant financial relationships to disclose:

Mark Geisler; Kristina M. Gregory, RN, MSN, OCN; Kristin Kline Hasson; Rose Joyce; Joan S. McClure, MS; Diane McPherson; Melanie Moletzsky; Deborah Moonan, RN, BSN; Lisa Perfidio; Liz Rieder; Shannon K. Ryan; Kathy Smith; Jennifer McCann Weckesser

The NCCN clinical information team listed below, who have reviewed content, has no relevant financial relationships to disclose:

Miranda Hughes, PhD

The ACCME/ANCC/ACPE defines “conflict of interest” as when an individual has an opportunity to affect CE content about products or services of a commercial interest with which he/she has a financial relationship.

ACCME, ACPE, and ANCC focuses on financial relationships with commercial interests in the 12-month period preceding the time that the individual is being asked to assume a role controlling content of the CE activity. ACCME, ACPE, and ANCC have not set a minimal dollar amount for relationships to be significant. Inherent in any amount is the incentive to maintain or increase the value of the relationship. The ACCME, ACPE, and ANCC defines “’relevant’ financial relationships” as financial relationships in any amount occurring within the past 12 months that create a conflict of interest.

All faculty for this continuing education activity are competent in the subject matter and qualified by experience, training, and/or preparation to the tasks and methods of delivery.

Physicians
National Comprehensive Cancer Network (NCCN) is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education to physicians.

National Comprehensive Cancer Network designates this live activity for a maximum of 1.0 AMA PRA Category 1 Credits™. Physicians should only claim credit commensurate with the extent of their participation in the activity.

Nurses
National Comprehensive Cancer Network (NCCN) is accredited as a provider of continuing nursing education by the American Nurses Credentialing Center’s (ANCC) Commission on Accreditation. NCCN designates this educational activity for a maximum of 1.0 contact hours. Accreditation as a provider refers to the recognition of educational activities only; accredited status does not imply endorsement by NCCN or ANCC of any commercial products discussed/displayed in conjunction with the educational activity.

Kristina M. Gregory, RN, MSN, OCN, is our lead nurse planner for this educational activity.

Case Managers
This program has been pre-approved by The Commission for Case Manager Certification to provide continuing education credit to CCM® board certified case managers. The course is approved for 1.0 CE contact hour(s).  Activity Code: I00023425; Approval #: 160003891

Pharmacists

National Comprehensive Cancer Network is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education.

Type of Activity: Knowledge

National Comprehensive Cancer Network designates this continuing education activity for 1.0 contact hour(s) (0.1 CEUs) of continuing education credit in states that recognize ACPE accredited providers.

Universal Activity Number: 0836-0000-16-103-L01-P

Available Credit

  • 1.00 ACPE contact hours
  • 1.00 AMA PRA Category 1 Credit™
  • 1.00 ANCC contact hours
  • 1.00 CCM clock hours
  • 1.00 Participation

Price

Cost:
$0.00
Please login or register to take this course.

Required Hardware/software

To complete this activity, users will need:

  • A device with an Internet connection and sound playback capability
  • Adobe Reader or other PDF reader software for certificate viewing/printing